3 Stocks I Bought That Could Produce 10X Returns

75
Comment
1

3 Stocks I Bought That Could Produce 10X Returns

Motley Fool2021-09-15

I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

WLtan
·2021-09-16
Great
Reply
1
Report
ricebowl
·2021-09-15
Oh yeah
Reply
4
Report
Huatkor
·2021-09-15
Like please
Reply
4
Report
Fold Replies
- ricebowl:
  Okie
  2021-09-15
  Reply
  Report
ImMillionare
·2021-09-15
?
Reply
7
Report
Fold Replies
- Cher883:
  Great!
  2021-09-16
  Reply
  Report
- WLtan:
  wow
  2021-09-16
  Reply
  Report
Calvinq
·2021-09-15
Like comment pls. PYPL ?
Reply
2
Report
Fold Replies
- aloyyyyyy:
  done
  2021-09-15
  Reply
  Report
- JusTinFoo:
  To the moon
  2021-09-15
  Reply
  Report
Dalex1212
·2021-09-15
Nice
Reply
4
Report
NPC69
·2021-09-15
Like
Reply
2
Report
PengsieX
·2021-09-15
Please write a follow up article
Reply
4
Report
Fold Replies
- HueiKwang:
  FollowUp
  2021-09-15
  Reply
  Report
- MinM:
  Yeaa
  2021-09-15
  Reply
  Report
Tohyx
·2021-09-15
Tiger
Reply
3
Report
Fold Replies
- dallanube:
  or cat in disguise
  2021-09-15
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2167598802?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-15 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2167598802","market":"us","top_or_hot":-1,"title":"3 Stocks I Bought That Could Produce 10X Returns","media":"Motley Fool","content":"<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ME","symbol_name":"23andMe, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","article_id":"2167598802","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","pubTimestamp":1631713921,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ME":"23andMe, Inc.","MELI":"MercadoLibre","OPAD":"Offerpad Solutions"},"translate_title":"我买了3只能产生10倍回报的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ME":0.9,"MELI":0.9,"OPAD":0.9},"content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":885052801,"gmtCreate":1631747850503,"gmtModify":1676530622419,"author":{"id":"3581912064711553","authorId":"3581912064711553","name":"WLtan","avatar":"https://static.tigerbbs.com/354ffef504de8ee7159ec0ecd8769350","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885052801","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":882476997,"gmtCreate":1631717372919,"gmtModify":1676530617779,"author":{"id":"3578561901514206","authorId":"3578561901514206","name":"ricebowl","avatar":"https://static.tigerbbs.com/a9ec802718dde5068862a7df929de4ed","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Oh yeah&nbsp;","listText":"Oh yeah&nbsp;","text":"Oh yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882476997","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":882458565,"gmtCreate":1631716383057,"gmtModify":1676530617272,"author":{"id":"3581919183376534","authorId":"3581919183376534","name":"Huatkor","avatar":"https://static.tigerbbs.com/6f3897aace055b5fa9f58089c1e880d8","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/882458565","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5879904,"gmtCreate":1631717381876,"gmtModify":1663233930650,"authorId":3578561901514206,"author":{"id":3578561901514206,"authorId":3578561901514206,"name":"ricebowl","avatar":"https://static.tigerbbs.com/a9ec802718dde5068862a7df929de4ed","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.99%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":882458565,"type":1,"supId":0,"prevId":0,"content":"Okie","text":"Okie","html":"Okie"}],"langContent":"EN"},{"id":882427569,"gmtCreate":1631716160451,"gmtModify":1676530617175,"author":{"id":"4087478892860850","authorId":"4087478892860850","name":"ImMillionare","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/882427569","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5884803,"gmtCreate":1631755757367,"gmtModify":1663233948636,"authorId":3567659784760386,"author":{"id":3567659784760386,"authorId":3567659784760386,"name":"Cher883","avatar":"https://static.tigerbbs.com/0f4ff9dfb85f525d8b47cd4b6f48548f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":882427569,"type":1,"supId":0,"prevId":0,"content":"Great!","text":"Great!","html":"Great!"},{"id":5882568,"gmtCreate":1631747873438,"gmtModify":1663233941132,"authorId":3581912064711553,"author":{"id":3581912064711553,"authorId":3581912064711553,"name":"WLtan","avatar":"https://static.tigerbbs.com/354ffef504de8ee7159ec0ecd8769350","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":882427569,"type":1,"supId":0,"prevId":0,"content":"wow","text":"wow","html":"wow"}],"langContent":"EN"},{"id":882489636,"gmtCreate":1631714751925,"gmtModify":1676530616434,"author":{"id":"3581665869451416","authorId":"3581665869451416","name":"Calvinq","avatar":"https://static.tigerbbs.com/3c005973d00b3597177b005554456e28","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like comment pls. PYPL ?","listText":"Like comment pls. PYPL ?","text":"Like comment pls. PYPL ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/882489636","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5879553,"gmtCreate":1631715987617,"gmtModify":1663233928238,"authorId":3577171842376403,"author":{"id":3577171842376403,"authorId":3577171842376403,"name":"aloyyyyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":882489636,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"},{"id":5879571,"gmtCreate":1631716042324,"gmtModify":1663233926242,"authorId":3582497749494276,"author":{"id":3582497749494276,"authorId":3582497749494276,"name":"JusTinFoo","avatar":"https://static.tigerbbs.com/7656eaa5bcdc2424dadea0ecdd268d11","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":882489636,"type":1,"supId":0,"prevId":0,"content":"To the moon","text":"To the moon","html":"To the moon"}],"langContent":"EN"},{"id":882414645,"gmtCreate":1631714532287,"gmtModify":1676530616356,"author":{"id":"3585697030979497","authorId":"3585697030979497","name":"Dalex1212","avatar":"https://static.tigerbbs.com/bc5e5de5db287690289de51a25c7cfb0","vip":1,"crmLevel":9,"crmLevelSwitch":1},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882414645","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":882414045,"gmtCreate":1631714523687,"gmtModify":1676530616342,"author":{"id":"3584779133668268","authorId":"3584779133668268","name":"NPC69","avatar":"https://static.tigerbbs.com/47e7ac55312ae8dd1c9e7cb92adad089","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882414045","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":882435580,"gmtCreate":1631714030340,"gmtModify":1676530615974,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":4,"crmLevelSwitch":0},"htmlText":"Please write a follow up article&nbsp;","listText":"Please write a follow up article&nbsp;","text":"Please write a follow up article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/882435580","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5879126,"gmtCreate":1631714424756,"gmtModify":1663233926428,"authorId":3576803977335172,"author":{"id":3576803977335172,"authorId":3576803977335172,"name":"HueiKwang","avatar":"https://static.tigerbbs.com/0b383f4a30ca6333c52769097600ed0b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":882435580,"type":1,"supId":0,"prevId":0,"content":"FollowUp","text":"FollowUp","html":"FollowUp"},{"id":5879137,"gmtCreate":1631714464390,"gmtModify":1663233924744,"authorId":4087383341767170,"author":{"id":4087383341767170,"authorId":4087383341767170,"name":"MinM","avatar":"https://static.tigerbbs.com/c8411a47d0234f2f75d808e208478f31","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":882435580,"type":1,"supId":0,"prevId":0,"content":"Yeaa","text":"Yeaa","html":"Yeaa"}],"langContent":"EN"},{"id":882435331,"gmtCreate":1631713998023,"gmtModify":1676530615964,"author":{"id":"3577615424644075","authorId":"3577615424644075","name":"Tohyx","avatar":"https://static.tigerbbs.com/09925fd9e75b6221e2e1ebab3f7bff4e","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":5,"crmLevelSwitch":1},"htmlText":"Tiger","listText":"Tiger","text":"Tiger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/882435331","repostId":2167598802,"repostType":4,"repost":{"id":"2167598802","pubTimestamp":1631713921,"share":"https://www.laohu8.com/m/news/2167598802?lang=&edition=full","pubTime":"2021-09-15 21:52","market":"us","language":"en","title":"3 Stocks I Bought That Could Produce 10X Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2167598802","media":"Motley Fool","summary":"These aren't exactly low-risk stocks, but the long-term potential could be enormous.","content":"<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of <b>Square</b> (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.</p>\n<p>With that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8185bbb3120982d2f5fdebc1009713b8\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Real estate agents beware</h2>\n<p>One of the most speculative stocks I ever bought is <b>Offerpad</b> (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.</p>\n<p>If you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.</p>\n<p>The company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.</p>\n<p>As if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.</p>\n<h2>The Amazon of Latin America</h2>\n<p>By far, <b><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> </b>(NASDAQ:MELI) is the most established business of the three. Often referred to as the <b>Amazon</b> (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> </b>(NASDAQ:PYPL), which was a part of <a href=\"https://laohu8.com/S/EBAY\">eBay</a> and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.</p>\n<p>So far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.</p>\n<p>While these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.</p>\n<p>MercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.</p>\n<h2>A potentially transformative healthcare stock</h2>\n<p>Another recent SPAC IPO I bought is<b> 23andMe</b> (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.</p>\n<p>23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with <b>GlaxoSmithKline</b> (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.</p>\n<p>To be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.</p>\n<h2>Approach these with patience and caution</h2>\n<p>As a final thought, it's important to emphasize that I own all three of these as <i>long-term</i> investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Bought That Could Produce 10X Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Bought That Could Produce 10X Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MELI":"MercadoLibre","ME":"23andMe, Inc.","OPAD":"Offerpad Solutions"},"source_url":"https://www.fool.com/investing/2021/09/15/3-stocks-i-bought-that-could-produce-10x-returns/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167598802","content_text":"I tend to be a more conservative investor than most of my colleagues. For the most part, my portfolio is filled with slow-and-steady stocks like real estate investment trusts, banks, and large blue-chip companies. However, I also like to allocate some of my portfolio to exciting growth stocks that could have massive long-term potential. This is how I came to own shares of Square (NYSE:SQ) for an $11 price tag just after its IPO (currently around $250), to name one example.\nWith that in mind, I've recently added a few exciting growth stocks to my portfolio, and here are three in particular that could have the potential to produce massive returns over the next decade and beyond if things go well.\nImage source: Getty Images.\nReal estate agents beware\nOne of the most speculative stocks I ever bought is Offerpad (NYSE:OPAD), which I recently added to my portfolio after the company went public via SPAC merger.\nIf you aren't familiar, Offerpad is an iBuyer, which is a company that buys homes directly from sellers, makes cosmetic repairs, and then sells them directly to homebuyers (hopefully) at a profit. Not only is Offerpad one of the few companies laser-focused on the iBuying business, but it is arguably the most efficient, earning a profit in the second quarter.\nThe company anticipates buying as many as 6,000 homes this year, but this could be just a starting point. There are roughly 2 million homes bought and sold in the U.S. each year, at a total price of more than $6 trillion.\nAs if that weren't enough, the iBuying market is just one way Offerpad could grow its business. The company also offers traditional brokerage services for sellers who want to see what their homes could get on the open market, title insurance, moving services, and mortgages. In the future, it aims to add things like insurance, home warranties, remodeling services, and more, effectively becoming a one-stop real estate solution.\nThe Amazon of Latin America\nBy far, MercadoLibre (NASDAQ:MELI) is the most established business of the three. Often referred to as the Amazon (NASDAQ:AMZN) of Latin America, MercadoLibre operates a large e-commerce marketplace in Brazil, Argentina, and several other Latin American nations. It also operates a payment processing platform called Mercado Pago. Think of Mercado Pago in the same context as an earlier-stage PayPal (NASDAQ:PYPL), which was a part of eBay and gradually branched out to dominate the entire online payment landscape in the U.S. and beyond.\nSo far, growth has been phenomenal. In the second quarter of 2021, MercadoLibre's marketplace saw $7 billion in merchandise volume, which was 46% higher year over year. Mercado Pago is now processing payments at a $70 billion annualized pace, and the most important part (payment volume from outside the marketplace) grew by a staggering 94% year over year.\nWhile these numbers might sound huge, keep in mind that they represent roughly 4% of Amazon's merchandise volume and 6% of PayPal's payment volume, so there's still tons of room to grow.\nMercadoLibre started out as a value buy in my portfolio last March during the initial COVID-19 crash, and I've added to it several times since. It is now one of my largest holdings, and one I plan to keep for the long haul.\nA potentially transformative healthcare stock\nAnother recent SPAC IPO I bought is 23andMe (NASDAQ:ME), which recently went public through a blank-check company sponsored by Richard Branson's Virgin Group.\n23andMe is best known for its consumer-facing home genetics testing kits, and while this certainly is a promising revenue stream, it isn't the most exciting part of the business. The real potential comes from the massive database of consumer genetic information 23andMe continues to accumulate -- currently 11.6 million customers -- that could ultimately be applied to pharmaceutical research and development. 23andMe has a 50/50 drug development agreement with GlaxoSmithKline (NYSE:GSK), and there is currently one therapeutic in Phase 1 trials and another set to enter clinical trials next year.\nTo be sure, 23andMe is a long way from profitability. It lost $42 million in the most recent quarter on just $59 million in revenue. However, the long-term potential from the pharmaceutical side of the business is massive, and the risk-reward profile makes sense, especially considering that you can buy shares right now for less than Richard Branson did.\nApproach these with patience and caution\nAs a final thought, it's important to emphasize that I own all three of these as long-term investments. And while I feel they all have the potential to produce 10X returns (or far more), there's absolutely no guarantee. Offerpad and 23andMe in particular could have very binary outcomes over time. In short, these stocks are most appropriate for investors with relatively high risk tolerance and the patience to ride out the roller-coaster ride we'll likely see in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5879112,"gmtCreate":1631714366305,"gmtModify":1663233926350,"authorId":4089903454740810,"author":{"id":4089903454740810,"authorId":4089903454740810,"name":"dallanube","avatar":"https://static.tigerbbs.com/e0e048a9487083a6c3f00b24abf18511","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":882435331,"type":1,"supId":0,"prevId":0,"content":"or cat in <u>disguise</u>","text":"or cat in <u>disguise</u>","html":"or cat in <u>disguise</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":75,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}